Onyx Pharmaceuticals Inc
featured
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
» Read MoreMore
-
*FDA advisory panel votes against approval of tivozanib. May 2- An advisory panel to the U.S. Food and Drug Administration recommended that the agency reject a kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc, saying data from the clinical trial were inconsistent.
-
*FDA staff question sends Aveo shares down as much as 21.3 pct. April 30- Staff reviewers for the U.S. Food and Drug Administration will ask a panel of outside medical experts on Thursday whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc.
-
*FDA staff question sends Aveo shares down as much as 21.3 pct Staff wonder whether additional trial needed.
-
April 30- Staff reviewers for the U.S. Food and Drug Administration will ask a panel of outside medical experts if another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can be approved.
-
*Analysts provide mixed interpretations of FDA review. April 30- Staff reviewers for the U.S. Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc.
-
*Analysts provide mixed interpretations of FDA review. April 30- Staff reviewers for the U.S. Food and Drug Administration have asked a panel of outside medical experts whether another clinical trial is needed before an experimental kidney cancer drug made by Aveo Pharmaceuticals Inc and Astellas Pharma Inc can be approved.
-
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
-
Onyx Pharmaceuticals CEO Dr. Anthony Coles discusses his company's thyroid cancer drug and its blood cancer drug and its partnership with Bayer.
-
CNBC Contributor Barbara Ryan is taking the pulse of health care stocks at this year's "Woodstock" of health care.
-
Strong fundamentals and dominant market positions make three biotech/pharma names stand out, Barbara Ryan says.
